As of Jul 21
| +0.16 / +0.47%|
The 34 analysts offering 12-month price forecasts for AstraZeneca have a median target of 35.44, with a high estimate of 51.55 and a low estimate of 2.00. The median estimate represents a +4.07% increase from the last price of 34.05.
The current consensus among 39 polled investment analysts is to Buy stock in AstraZeneca. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.